NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · MID CAP
Anika Therapeutics, Inc. ANIK
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$112.8M
▼ 5.9% vs FY2024
EPS · FY25
$-0.76
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-7.3%
Net margin · FY25
-9.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 112.8M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 10 cents on every revenue dollar this year.
Per share
USD -0.76
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-7.3%
Return on equity, FY2025
ROE
Operating margin-9.8%
Net margin-9.6%
Return on assets-5.5%
Each USD of equity lost 7 cents this year.
Returned to shareholders
USD 9.5M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 9.5M
Share of profit-87.2%
Consecutive raises—
USD 9.5M in buybacks went back to shareholders in a year without profit.
Growth
−2.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.3%
−2.9%
+2.0%
+4.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years−3.1%
Change, 10 years−7.6%
The share count shrank 3% in five years — the same company, cut into fewer, larger slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 190.3M
total assets, end of FY2025
Total assetsUSD 190.3M
EquityUSD 143.5M
CashUSD 57.5M
Current ratio4.72×
Equity funds 75% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
Operating income $B
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.1
0.0
0.1
0.0
0.0
0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.1
−0.1
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
−0.76
−3.83
−5.64
−1.02
0.28
−1.69
1.89
1.27
2.11
2.15
2.01
2.51
1.39
0.82
0.62
0.32
0.32
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−7.3
−30.8
−33.2
−5.2
1.5
−8.6
9.9
7.1
13.1
15.0
15.8
24.4
16.8
11.5
9.4
5.2
4.5
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.02
0.01
0.01
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
57 of 57
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed